About
Cell Therapy for Sight Loss
Areas of Focus
Categories
Stem Cell & Cellular TherapyBoston & New England
Team (15)
Charles Wykoff
Clinical Advisor
InGel Therapeutics
advisor
Constance Cepko
Scientific Advisor
InGel Therapeutics
advisor
Dean Elliot
Clinical Advisor
InGel Therapeutics
advisor
Deepti Singh
Co-Founder & Chief Scientific Officer
InGel Therapeutics
executivefounder
Eliot Lazar
Business Advisor
InGel Therapeutics
advisor
Eric Nudleman
Clinical Advisor
InGel Therapeutics
advisor
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
2
As Collaborator
2
Total Enrollment
207
By Phase
PHASE1/PHASE2: 2PHASE1: 2
By Status
RECRUITING: 4
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06721689Collaborator
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
PHASE1/PHASE2Recruiting
59 participants
Started: Mar 23, 2025 · Completed: Apr 30, 2031
NCT06709495Collaborator
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
PHASE1/PHASE2Recruiting
63 participants
Started: Jan 27, 2025 · Completed: Sep 1, 2029
NCT05200650Lead Sponsor
A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor
PHASE1Recruiting
20 participants
Started: Jan 15, 2023 · Completed: Jul 1, 2025
NCT05329103Lead Sponsor
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
PHASE1Recruiting
65 participants
Started: Jul 11, 2022 · Completed: Mar 31, 2026
Funding History (1)
D
Aug 26, 2022
Locations (1)
Headquarters
Allston, MA, United States
Map
Loading map...